Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thrust & Parry: CVT And Gilead Look To Lock Out Astellas With Planned Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead’s surprise $20 per share bid tops Astellas’ $16 per share offer, highlights Gilead’s increasing focus on cardiovascular space.

You may also be interested in...



Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders

To publicize its hostile bid for OSI Pharmaceuticals, Astellas Pharma has registered the Web site oncologyleader.com. Call it hopefulness, call it hubris, but in the race to build an oncology business, Astellas is as far back in the pack as a 14,000-person global pharmaceutical firm can be

Astellas Takes Hostile $3.5 Bil. Bid To OSI Shareholders

To publicize its hostile bid for OSI Pharmaceuticals, Astellas Pharma has registered the Web site oncologyleader.com. Call it hopefulness, call it hubris, but in the race to build an oncology business, Astellas is as far back in the pack as a 14,000-person global pharmaceutical firm can be

Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI

Japan's second-biggest pharma offers $3.5 billion to OSI shareholders after 13 months of rejection by the target's management.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel